Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous tumor lysate-loaded dendritic cell vaccine (Dartmouth-Hitchcock)
- Development stage
- Unknown
- Lead developer
- Dartmouth Hitchcock Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranodal
01
Overview
This autologous dendritic cell-based vaccine is a personalized cellular immunotherapy developed at Dartmouth-Hitchcock Medical Center for the treatment of metastatic renal cell carcinoma (mRCC). The vaccine is produced by harvesting peripheral blood monocytes from the patient, which are then differentiated into dendritic cells ex vivo and loaded with autologous tumor lysate. This loading process allows the dendritic cells to present a comprehensive and individualized array of tumor-associated antigens specific to the patient's own malignancy. Administered via intranodal injection, the vaccine aims to prime and activate the patient's T-cells to recognize and destroy tumor cells. In clinical development, this vaccine has been studied in combination with systemic immunotherapies such as aldesleukin (IL-2) and interferon-alpha-2b, as well as the anti-VEGF monoclonal antibody bevacizumab, to enhance the overall anti-tumor immune response.
- Other names
- Dendritic Cell vaccine-Dartmouth-Hitchcock Medical Center-metastatic renal cell carcinomaAutologous tumor/dendritic cell vaccineDartmouth-Hitchcock DC vaccine
Beyond the preview
Go deeper on Autologous tumor lysate-loaded dendritic cell vaccine (Dartmouth-Hitchcock).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous tumor lysate-loaded dendritic cell vaccine (Dartmouth-Hitchcock).